Trials / Recruiting
RecruitingNCT07523477
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis
Evaluation of Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with : A-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.
Detailed description
Dysfunctional voiding (DV) is a habitual voiding disorder caused by involuntary contraction or non relaxation of the external urethral sphincter (EUS) during voiding. This contraction causes high post void residuals (PVR), The disorder can occur at any age. In young children it often presents as urinary incontinence, nocturnal enuresis, or recurrent urinary tract infections (UTIs). Nocturnal enuresis (NE) is common, affecting 15-20 % of children by five years old, and 8-10 % of children by eight years old. Refractory nocturnal enuresis is defined as monosymptomatic nocturnal enuresis (bedwetting without daytime urinary symptoms) that persists despite at least 3-6 months of appropriate and compliant first line therapy. Botulinum toxin has been found to inhibit the release of a number of neurotransmitters (including acetylcholine, adenosine triphosphate, and neuropeptides such as substance P) and to down regulate the expression of purinergic and capsaicin receptors on afferent neurons within the bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinium Toxin-A | Patients will be injected with botulinium toxin-A |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07523477. Inclusion in this directory is not an endorsement.